Effect of 7-con-O-methylnogarol on DNA synthesis, survival, and cell cycle progression of Chinese hamster ovary cells
- PMID: 6458356
Effect of 7-con-O-methylnogarol on DNA synthesis, survival, and cell cycle progression of Chinese hamster ovary cells
Abstract
The effect of 7-con-O-methylnogarol (7-OMEN) on the survival of exponentially growing and plateau-phase Chinese hamster ovary cells was determined in a cloning assay. After 2 hr of exposure, the 50% lethal dose for exponential and plateau-phase cells was 0.3 and 1.5 microgram/ml, respectively. Drug doses for cell progression studies were based upon drug lethality; therefore, higher doses were used for plateau than for exponential populations. The effect of 7-OMEN on cell progression was studied by DNA flow cytometry under the following conditions: (a) during 24 hr of continuous exposure of exponentially growing cells; (b) during recovery of exponential cells after 2 or 7 hr of drug exposure; and (c) during recovery of plateau-phase cells after 2 hr of exposure. Exponential cells exposed continuously for 24 hr progressed normally from M to G1 phase and from G1 to S phase, progression through S phase was slowed, and cells were ultimately blocked in G2 + M. Inhibition of S-phase progression was dose dependent, 0.2 microgram/ml having only slight effect and 1.0 microgram/ml accumulating a large fraction in S phase. Inhibition of S-phase progression correlated with DNA synthesis inhibition. Similar inhibitory effects were observed after pulsed (2- or 7-hr) exposure of exponential cells. 7-OMEN also blocked plateau-phase cells in G2 + M after 2 hr of exposure, but higher doses (3.0 microgram/ml) were required. Simultaneous exposure of exponential cells to Colcemid (which blocks cells in metaphase) and 1.0 microgram 7-OMEN per ml completely inhibited the expected increase in mitotic index, indicating that the G2 + M block observed by DNA flow cytometry was a block in G2 or prophase.
Similar articles
-
Cell kill kinetics of several nogalamycin analogs and adriamycin for Chinese hamster ovary, L1210 leukemia, and B16 melanoma cells in culture.Cancer Res. 1981 Jan;41(1):18-24. Cancer Res. 1981. PMID: 7448758
-
Effects of aclacinomycin on cell survival and cell cycle progression of cultured mammalian cells.Cancer Res. 1981 Jul;41(7):2728-37. Cancer Res. 1981. PMID: 6166368
-
Lethality of nogalamycin, nogalamycin analogs, and adriamycin to cells in different cell cycle phases.Cancer Res. 1980 Oct;40(10):3437-42. Cancer Res. 1980. PMID: 7438031
-
Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells.Cancer Res. 1992 Oct 15;52(20):5687-92. Cancer Res. 1992. PMID: 1394193
-
The biochemical pharmacology of nogalamycin and its derivatives.Pharmacol Ther. 1991;51(2):239-55. doi: 10.1016/0163-7258(91)90080-6. Pharmacol Ther. 1991. PMID: 1838416 Review.
Cited by
-
Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation.J Cell Biol. 1988 Feb;106(2):415-22. doi: 10.1083/jcb.106.2.415. J Cell Biol. 1988. PMID: 2448314 Free PMC article.
-
Drug sensitivity of ten human tumor cell lines compared to mouse leukemia (L1210) cells.Invest New Drugs. 1987;5(3):219-29. doi: 10.1007/BF00175291. Invest New Drugs. 1987. PMID: 3667160
-
Phase II evaluation of menogaril in patients with advanced cervical carcinoma. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.Invest New Drugs. 1991 Nov;9(4):349-51. doi: 10.1007/BF00183579. Invest New Drugs. 1991. PMID: 1839536 Clinical Trial.
-
Cytotoxicity of combinations of prostaglandin D2 (PGD2) and antitumor drugs for B16 melanoma cells in culture.Invest New Drugs. 1986;4(4):315-23. doi: 10.1007/BF00173504. Invest New Drugs. 1986. PMID: 3473056
-
Synergistic combination of menogarol and melphalan and other two drug combinations.Invest New Drugs. 1985;3(3):233-44. doi: 10.1007/BF00179427. Invest New Drugs. 1985. PMID: 2933360